We are live on !
Find out more
Pavaki Capital Management Portfolio holdings
AUM
$294M
Turnover
9.94%
1-Year Est. Return
34.46%
This Fund
S&P 500
This Quarter Est. Return
+6.28%
1 Year Est. Return
+34.46%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$294M
AUM Growth
+$7.41M
(+2.6%)
Cap. Flow
+$21.1M
Cap. Flow % of AUM
Cap. Flow %
7.18%
Top 10 Holdings %
Top 10 Hldgs %
54.15%
Holding
171
New
8
Increased
11
Reduced
9
Closed
9
Avg Time Held
Equity + Options
0.6
years
Top 10 Avg Time Held
Equity + Options
0.5
years
Top 20 Avg Time Held
Equity + Options
0.6
years
Avg Time Held Equity only
0.6
years
Top 10 Avg Time Held Equity only
0.5
years
Top 20 Avg Time Held Equity only
0.6
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$22.3M |
| 2 |
Chevron
CVX
|
+$1.18M |
| 3 |
Regeneron Pharmaceuticals
REGN
|
+$1.06M |
| 4 |
Textron
TXT
|
+$555K |
| 5 |
ARS Pharmaceuticals
SPRY
|
+$468K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Advanced Micro Devices
AMD
|
+$2.32M |
| 2 |
Nokia
NOK
|
+$930K |
| 3 |
Replimune Group
REPL
|
+$890K |
| 4 |
SSR Mining
SSRM
|
+$711K |
| 5 |
Intel
INTC
|
+$559K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 33.84% |
| 2 | Technology | 19.25% |
| 3 | Healthcare | 16.34% |
| 4 | Materials | 10.75% |
| 5 | Energy | 10.51% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
CALL
Carvana
CVNA
$79.8B
| $37.8M | 12.86% |
605,000
| – | – |
2025 Q4
3 quarters
|
|
|
2
NVIDIA
NVDA
$3.93T
| $29.7M | 10.09% |
130,000
+104,000
| +400% | +$22.3M |
2025 Q4
3 quarters
|
|
|
3
Chevron
CVX
$429B
| $21M | 7.15% |
103,000
+6,000
| +6% | +$1.18M |
2025 Q4
3 quarters
|
|
4
CALL
Tesla
TSLA
$1.54T
| $15.8M | 5.37% |
44,500
+1,000
| +2% | +$358K |
2025 Q4
3 quarters
|
|
5
Intuit
INTU
$91.3B
| $10.6M | 3.62% |
38,600
| – | – |
2026 Q2
1 quarter
|
|
6
CALL
Palantir
PLTR
$405B
| $9.45M | 3.21% |
50,500
| – | – |
2025 Q4
3 quarters
|
|
7
Barrick Mining
B
$61.2B
| $9.21M | 3.13% |
226,500
+5,000
| +2% | +$205K |
2025 Q4
3 quarters
|
|
8
Qualcomm
QCOM
$185B
| $9.02M | 3.06% |
49,000
| – | – |
2026 Q2
1 quarter
|
|
|
9
Regeneron Pharmaceuticals
REGN
$98.8B
| $8.57M | 2.91% |
11,300
+1,400
| +14% | +$1.06M |
2025 Q4
3 quarters
|
|
10
Milestone Pharmaceuticals
MIST
$64.7M
| $8.08M | 2.75% |
9,337,848
+270,000
| +3% | +$300K |
2025 Q4
3 quarters
|
|
|
11
Textron
TXT
$14.2B
| $6.92M | 2.35% |
90,800
+6,500
| +8% | +$555K |
2025 Q4
3 quarters
|
|
12
B2Gold
BTG
$6.47B
| $6.16M | 2.09% |
1,180,000
| – | – |
2025 Q4
3 quarters
|
|
13
PUT
Invesco QQQ Trust
QQQ
$461B
| $5.18M | 1.76% |
7,000
-16,000
| -70% | -$11.4M |
2025 Q4
3 quarters
|
|
14
Arcutis Biotherapeutics
ARQT
$3.57B
| $4.94M | 1.68% |
187,000
| – | – |
2025 Q4
3 quarters
|
|
15
Micron Technology
MU
$881B
| $4.26M | 1.45% |
4,000
| – | – |
2026 Q2
1 quarter
|
|
16
Centerra Gold
CGAU
$3.92B
| $3.86M | 1.31% |
177,000
-20,000
| -10% | -$402K |
2025 Q4
3 quarters
|
|
17
Newmont
NEM
$118B
| $3.75M | 1.27% |
32,500
| – | – |
2025 Q4
3 quarters
|
|
18
Ligand Pharmaceuticals
LGND
$6.18B
| $3.47M | 1.18% |
11,100
| – | – |
2025 Q4
3 quarters
|
|
|
19
CALL
Invesco QQQ Trust
QQQ
$461B
| $3.33M | 1.13% |
4,500
| – | – |
2025 Q4
3 quarters
|
|
20
SLB Ltd
SLB
$76.3B
| $2.97M | 1.01% |
61,000
| – | – |
2026 Q1
2 quarters
|
|
21
Harmony Biosciences
HRMY
$1.98B
| $2.87M | 0.97% |
73,000
| – | – |
2025 Q4
3 quarters
|
|
|
22
ARS Pharmaceuticals
SPRY
$391M
| $2.84M | 0.97% |
659,600
+80,000
| +14% | +$468K |
2025 Q4
3 quarters
|
|
23
Royalty Pharma
RPRX
$30.9B
| $2.57M | 0.87% |
44,000
| – | – |
2025 Q4
3 quarters
|
|
24
CALL
Broadcom
AVGO
$1.66T
| $2.46M | 0.84% |
7,000
| – | – |
2025 Q4
3 quarters
|
|
25
Bio-Rad Laboratories Class A
BIO
$9.9B
| $2.27M | 0.77% |
6,000
| – | – |
2025 Q4
3 quarters
|
|
Similar funds
SM
Pavaki Capital Management's Q3 2026 Portfolio in Review
As of Q3 2026, Pavaki Capital Management held 171 positions worth $294M, up 2.6% from $287M the previous quarter. Its ten largest holdings account for 54% of the portfolio.
Pavaki Capital Management deployed $21.1M of net new capital in Q3 2026, opening 8 new positions and adding to 11 existing holdings. Its largest new stake was Caris Life Sciences: 20,000 shares worth $613K.
By sector, the portfolio is most concentrated in Miscellaneous at 34% of assets, down from 41% a quarter earlier, followed by Technology and Healthcare.
On the sell side, the largest reduction was SSR Mining, an estimated $711K trimmed.
- Pavaki Capital Management's largest Q3 2026 buy was Caris Life Sciences: 20,000 shares worth $613K.
- Pavaki Capital Management added most to NVIDIA in Q3 2026, an estimated $22.3M increase.
- Pavaki Capital Management's biggest Q3 2026 reduction was SSR Mining, cutting an estimated $711K.
- Pavaki Capital Management fully exited Advanced Micro Devices in Q3 2026, selling an estimated $2.32M.
- Pavaki Capital Management's ten largest holdings make up 54% of its $294M portfolio in Q3 2026.
- Pavaki Capital Management opened 8 new positions and closed 9 in Q3 2026.
- Pavaki Capital Management's portfolio value rose 2.6% quarter-over-quarter to $294M.
Based on Pavaki Capital Management's 13F filing for Q3 2026, filed 26 Oct 2026.